PET Imaging for Breast Cancer

Amy M Fowler; Steve Y Cho

doi:10.1016/j.rcl.2021.05.004

PET Imaging for Breast Cancer

Radiol Clin North Am. 2021 Sep;59(5):725-735. doi: 10.1016/j.rcl.2021.05.004.

Authors

Amy M Fowler¹, Steve Y Cho²

Affiliations

¹ Breast Imaging and Intervention Section, Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792-3252, USA; Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, 1111 Highland Avenue, Madison, WI 53705, USA; University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA. Electronic address: afowler@uwhealth.org.
² University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA; Nuclear Medicine and Molecular Imaging Section, Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792-3252, USA.

PMID: 34392915
DOI: 10.1016/j.rcl.2021.05.004

Abstract

Imaging plays an integral role in the clinical care of patients with breast cancer. This review article focuses on the use of PET imaging for breast cancer, highlighting the clinical indications and limitations of 2-deoxy-2-[¹⁸F]fluoro-d-glucose (FDG) PET/CT, the potential use of PET/MRI, and 16α-[¹⁸F]fluoroestradiol (FES), a newly approved radiopharmaceutical for estrogen receptor imaging.

Keywords: (18)F-FDG; (18)F-FES; Breast cancer; Computed tomography; Magnetic resonance imaging; Positron emission tomography.

Publication types

Review

MeSH terms

Breast Neoplasms / diagnostic imaging*
Breast Neoplasms / pathology*
Female
Fluorodeoxyglucose F18
Humans
Magnetic Resonance Imaging
Neoplasm Staging
Positron Emission Tomography Computed Tomography / trends*
Positron-Emission Tomography
Radiopharmaceuticals

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18